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In the Netherlands, 1.4% of tuberculosis (TB) cases 
are caused by Mycobacterium bovis. After we admitted 3 
patients with M. bovis infections to our reference hospital, 
we conducted a retrospective analysis of all M. bovis 
disease in the Netherlands during 1993–2007. We analyzed 
data from 231 patients for clinical, demographic, treatment, 
and outcome characteristics and for risk factors. Most 
patients were native Dutch (n = 138; 59.7%) or Moroccan 
(n = 54; 23.4%). Disease was mainly extrapulmonary (n = 
136; 58.9%). Although 95 patients had pulmonary disease, 
person-to-person transmission did not occur, as shown 
by structural DNA ﬁ  ngerprinting analysis. Lymph node TB 
was more likely to develop in women (p<0.0001), whereas 
pulmonary M. bovis disease developed more frequently in 
men (p<0.0001). Diagnosis was accurate but delayed and 
led to inadequate treatment in 26% of the cases. Proportion 
of deaths from M. bovis disease was higher than that for M. 
tuberculosis disease.
M
ycobacterium bovis disease was common in the 
Western world in the era before pasteurization 
of milk products. In 1938, the percentage of M. bovis 
disease among all patients with tuberculosis (TB) was 9% 
in Amsterdam and 11% in the rest of the Netherlands. In 
1940, pasteurization became obligatory, and in 1952, the 
percentage of M. bovis disease had dropped to 1.5%–2.0% 
in Amsterdam (1,2). From 1945 until the mid-1960s, M. 
bovis infection was gradually eradicated in livestock in the 
Netherlands. Nevertheless, during 1973–1975, ≈2.5% of 
the human TB cases in the Netherlands were still caused 
by M. bovis (3). Since 1993, only 10 cases of M. bovis 
infection have occurred in livestock in the Netherlands. All 
were caused by infected livestock that had been imported 
(D. Bakker, pers. comm.). Because most M. bovis infections 
are contracted through the oral route, extrapulmonary 
manifestations were primarily observed. 
Diagnosing extrapulmonary TB is generally difﬁ  cult, 
and as the prevalence of TB has declined, the experience 
of physicians in diagnosing this speciﬁ  c infectious disease 
has also decreased, and therefore the time to diagnosis 
has increased (4,5). The difﬁ  culties in the diagnosis and 
treatment of M. bovis infections in 3 female patients at 
the University Centre for Chronic Diseases Dekkerswald 
prompted the present study. To investigate the magnitude 
of M. bovis infection in persons in the Netherlands, we 
conducted a retrospective study of patients with M. bovis 
infection and describe the epidemiologic, clinical, and 
bacteriologic ﬁ  ndings.
Materials and Methods
We retrieved data from 2 databases: one at the 
National Institute for Public Health and the Environment 
(RIVM), Bilthoven, the Netherlands, which contains the 
bacteriologic information of all M. tuberculosis complex 
isolates in the Netherlands. The other is the Netherlands 
Tuberculosis Register (NTR), an anonymous case register 
held by KNCV Tuberculosis Foundation in The Hague, 
the Netherlands. This database is based on voluntary 
registration but contains data from virtually all TB patients 
in the Netherlands.
The patients in the NTR database have been registered 
by their physicians. This register holds basic demographic, 
clinical, and some bacteriologic data. Death is registered as 
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TB related or not TB related without further explanation. 
Treatment and treatment outcome are registered without 
further details. Exact treatment length could be determined 
because length was registered in 2 different categories. 
Therefore, we could categorize treatment length in 6 
groups, namely <3 months, 4–5 months, 6 months, 7–9 
months, 10–12 months, and >12 months. 
We selected all M. bovis cases that occurred during 
1993–2007. By using these 2 databases we had information 
on bacteriologic and clinical factors, demographic data, 
and risk factors, as well as treatment and outcome. We 
used the RIVM database for the bacteriologic data and 
localization of the infections and the NTR database for 
the demographic and clinical data, including treatment 
outcome. To distinguish M. bovis caprae and M. bovis 
bovis infections, we reviewed available data on IS6110 
restriction fragment length polymorphism, spoligotyping, 
and pyrazinamide susceptibility for all M. bovis isolates 
analyzed in this study (6,7). Because IS6110 typing of all 
M. tuberculosis complex isolates is routinely performed in 
the Netherlands, we also analyzed information on possible 
interhuman transmission of M. bovis.
Associations between localization of infection in 
the patient, geographic distribution, ethnicity, etc. were 
evaluated on basis of information from both databases by 
using the χ2 test. Mortality rates were evaluated by using the 
NTR database and were correlated with the demographic 
and clinical data.
Case Reports 
Patient 1
A 73-year-old woman sought treatment for 
nonproductive cough and dyspnea. Medical history 
included severe rheumatoid arthritis, for which she had 
received treatment with anti–tumor necrosis factor-α 
(TNF-α) for 1 year. High-resolution computed tomography 
(CT) imaging of the thorax showed micronodular lesions 
in both lungs. CT imaging of the brain indicated several 
cerebral nodular lesions, suspected to be tuberculomas. 
Culture of bronchoalveolar lavage ﬂ  uid  yielded  M. 
bovis. The patient was treated with isoniazid, rifampin, 
and ethambutol. Moxiﬂ  oxacin and steroids were added, 
because of the high penetration level through the blood–
brain barrier of moxiﬂ  oxacin and to compensate for the 
absence of pyrazinamide in the treatment regimen.
Patient 2
An 84-year-old woman with a medical history of 
myelodysplastic syndrome and diabetes mellitus type 2 
sought treatment for a traumatic leg wound that did not 
heal, and her condition gradually progressed to generalized 
skin lesions. She was referred to the dermatologist in 
our hospital. Culture of a skin biopsy specimen grew M. 
bovis. The patient had lesions on her tongue, typical of 
TB (Figure 1), and on her the larynx and in her lungs. The 
patient’s condition resolved after 9 months of treatment 
with isoniazid, rifampin, and ethambutol. Contact tracing 
showed no human transmission.
Patient 3
An 87-year-old woman with severe rheumatoid 
arthritis sought treatment for weight loss, cough, night 
sweats, and dyspnea 1 year after starting anti–TNF-α 
treatment. Radiologic imaging showed a single nodular 
lesion of the lung parenchyma and pleural ﬂ  uid. Culture of 
a bronchoalveolar lavage specimen yielded M. bovis. The 
patient received isoniazid, ethambutol, and moxiﬂ  oxacin 
for 18 months because she had an intolerance for rifampin. 
No contact tracing was performed.
Results
During 1993–2007, a total of 16,059 patients were 
registered in the NTR with culture-proven TB; 231 (1.4%) 
patients were registered with M. bovis infection (8) (Figure 
2). The number of patients with M. bovis infection born 
outside the Netherlands (foreign-born) showed an increase 
in the proportion from 35.1% to 46.3% in the 1ast 5 years 
of the study period (Figure 3). Over time, the percentage 
of patients with M. bovis TB who live in major cities 
increased from 33.3% to 41.8%, with an accompanying 
decline elsewhere in the Netherlands. No relation was 
found between outbreaks in livestock and human disease.
Among patients with M. bovis disease, a signiﬁ  cant 
difference in mean age was noted among those born in the 
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Figure 1. Mycobacterium bovis lesion on the tongue of patient 2, 
the Netherlands.M. bovis Disease, the Netherlands
Netherlands and immigrants. In native Dutch persons with 
M. bovis disease, the median age was 64.8 years, whereas 
among immigrants, the median age was 38.6 years (Figure 
4). We observed 58 cases in young foreign-born patients 
and 16 cases in young Dutch patients (<40 years). Five 
Dutch patients had a general risk factor for contracting M. 
tuberculosis complex disease (1 with drug addiction, 1 with 
alcohol addiction, and 3 with risk factors not speciﬁ  ed) 
and 44 foreign-born had 1 or 2 general risk factors (32 
immigrants, 8 with fugitive status, 3 illegal immigrants, 
and 1 TB contact, 1 in criminal detention, 1 with risk factor 
not speciﬁ  ed).
Most of the patients were native Dutch (138 [59.7%] 
of 231). Most foreign-born patients came from Morocco 
(54 [23.4%] of 231). The other immigrants had other places 
of origin: Europe (n = 6; 2.6%), Africa (n = 15; 6.5%), Asia 
(n = 9; 3.9%), and South America (n = 3; 1.3%) (Table 1). 
A distinction between native Dutch and second-generation 
Dutch immigrants could not be made.
M. bovis TB mainly had appeared as extrapulmonary 
disease; 136 (58.9%) of 231 patients had extrapulmonary 
disease alone, 68 (29.4%) of 231 had pulmonary M. bovis 
disease, and 27 (11.7%) of 231 had both pulmonary and 
extrapulmonary disease. A signiﬁ  cant difference between 
men and women was found in terms of localization of 
disease. In women, lymph node TB was more likely to 
develop, mainly in the cervical region (p<0.0001); men 
more often had pulmonary M. bovis disease (p<0.0001). 
This ﬁ  nding was seen in all age groups in both Dutch and 
foreign-born patients. (Table 1)
Several treatment schedules were used for our study 
population; 157 of 231 patients received a combination 
of isoniazid, rifampin, ethambutol, and pyrazinamide, 
or another pyrazinamide-containing antimicrobial drug 
combination. Treatment with pyrazinamide-containing 
regimens had no negative effect on treatment outcome.
According to World Health Organization (WHO) 
standards, a regimen of isoniazid and rifampin for 9 months 
and ethambutol for 2 months is indicated for treating M. 
bovis disease. In our study population, we noted that 
113 (52%) of 217 patients were cured and completed 
treatment according to the WHO standard. Thirty-seven 
(17%) of 217 patients were considered cured with an 
insufﬁ  cient treatment schedule, duration, or both. For 14 
patients, outcome data were not available. No signiﬁ  cant 
associations were found between insufﬁ  cient treatment and 
particular disease localizations or outcome.
An anonymous questionnaire distributed to the 
physicians who were caring for the patients at the time of 
disease (34 sent and 24 returned) showed that most of the 
physicians followed the Dutch TB guidelines, which are 
based on the WHO standard. A problem these colleagues 
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Figure 2. Mycobacterium tuberculosis 
and M. bovis infections, the Netherlands, 
1993–2007. Data derived from the 
National Institute for Public Health and 
the Environment (RIVM) database.
Figure 3. Percentage of Mycobacterium 
bovis infections in foreign-born persons 
and total number of M. bovis infections, 
the Netherlands, 1993–2007. Data 
derived from the National Institute for 
Public Health and the Environment 
(RIVM) database.RESEARCH
faced was the time lag between sampling and the results of 
culture, identiﬁ  cation, and drug susceptibility tests, which 
sometimes took as long as 4 months.
Treatment outcome comparisons for Dutch and 
foreign-born patients in the Netherlands are shown in 
Table 2. The overall proportion of deaths for the infection 
itself was 5.2% for M. bovis disease, and the proportion of 
deaths associated with non–TB-related causes (e.g., cardiac 
disease and hematologic malignancy) for patients with M. 
bovis disease was 14.7%.
An analysis of the overall deaths from bovine TB 
according to sex, age, ethnicity, and disease localization is 
shown in Table 3. A correlation was found between death 
and age >60 years, Dutch nationality, and miliary disease. 
When dividing deaths into the categories of TB related and 
not–TB related, only high age was statistically signiﬁ  cant 
between the groups; all other variables were not signiﬁ  cant 
(Table 4). Cause and rate of death differed between sexes: 
among women, death was more often related to M. bovis 
TB; in men, the overall mortality rate was higher, although 
these differences were not statistically signiﬁ  cant.
Discussion
M. bovis TB comprised 1.4% of all TB cases in the 
Netherlands during 1993–2007. This ﬁ  nding is comparable 
to those of studies in other countries where control and 
corresponding control efforts of M. bovis TB in livestock 
are present (9–11). During 1993–1997, mainly elderly 
Dutch persons were found to have bovine TB; later (1998–
2007), the infections were divided more equally between 
the native Dutch and immigrants (Figure 3).
M. bovis TB in the population of the Netherlands shows 
an age curve with double peaks. The younger patients 
were mostly foreign-born or ﬁ  rst- and second-generation 
immigrants, who may have (frequently) traveled back to 
their country of origin or contracted an M. bovis infection 
by the oral route before coming to the Netherlands. 
These patients more often had extrapulmonary M. bovis 
disease, which mainly affected the cervical or abdominal 
lymph nodes. Ingestion of unpasteurized dairy products is 
the most likely route of infection (12,13). The 12 Dutch 
patients, ages 20–40 years, may have been in contact 
with nonpasteurized food while traveling to developing 
countries because the chance of contracting a M. bovis 
infection in the Netherlands is considered low.
The second age peak contains elderly native-born 
Dutch persons. This result is most likely a birth-cohort 
effect because these persons most probably had a late 
endogenous reactivation of latent M. bovis infection 
contracted in the era before pasteurization of milk was 
introduced and while M. bovis infection in livestock was 
still highly prevalent in the Netherlands. Spoligotyping 
of their isolates showed a single typical pattern, which is 
considered the old predominant cattle-endemic strain of 
the Netherlands (14). This epidemiologic trend has also 
been seen in other European countries, including Norway, 
Sweden, and Belgium (9,10).
Endogenous reactivation of M. bovis infections in 
elderly patients follows impairment of immunity from 
hematologic causes, immune modulation by medication 
(including anti–TNF-α treatment), other coexisting 
conditions, or immunosenescence. As the use of anti–
TNF-α treatment rises, due to increasing indications of 
rheumatologic and gastrointestinal diseases, mycobacterial 
disease will likely become more common (15). Two of 
the patients we described had negative tuberculin skin test 
(for M. tuberculosis complex) and chest radiograph results 
and, therefore did not receive isoniazid prophylaxis before 
they received anti–TNF-α treatment. This result calls into 
question the efﬁ  cacy of the screening protocol used in the 
Netherlands to evaluate patients before they receive anti–
TNF-α treatment. Of note, reactivations of latent TB usually 
occur in the ﬁ  rst 3–4 months of anti–TNF-α therapy (15), 
although in our 2 M. bovis patients, reactivation occurred 
after 1 year. This long-term asymptomatic reactivation of 
disease has been previously observed (16,17) and raises 
questions involving the role of the bacteriologic virulence 
factor in the pace of the reactivations.
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Figure 4. Number of Mycobacterium bovis 
infections, according to patient age and origin, 
the Netherlands, 1993–2007. Data derived from 
the National Tuberculosis Registry database.
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In the Netherlands, the 2 largest immigrant populations 
are from Turkey and Morocco (378,330 and 341,528 
persons, respectively) (18). A high occurrence of M. bovis 
disease was observed in Moroccan patients, whereas, to 
our surprise, M. bovis disease was rare in Turkish patients. 
Both populations come from agricultural areas where 
pasteurization of dairy products is not common. Popular 
raw milk cheeses in Morocco (jben) and Turkey (kasar, 
tulum) have been found to contain Listeria and Brucella 
species in as many as 8.2% of the samples tested (19,20). In 
both studies, cheeses were not tested for M. bovis. However, 
M. bovis can survive in raw milk cheese and cause an 
infection after it is eaten, as was described recently for a 
cluster of infections resulting from consumption of fresh 
Mexican cheese in New York and San Diego (12,13,21). 
Besides consumption of fresh cheese and unpasteurized 
milk, consumption of raw or undercooked meat is also a 
possible route of oral transmission (10,22,23).
More women than men were infected by M. bovis, 
contrary to the epidemiology of M. tuberculosis. Other 
studies about M. bovis do not show this result (9,11). This 
difference could be an age-related effect for Dutch patients; 
however, one can also see this difference in the Moroccan 
patient population (data not shown).
Notably, we also found a difference in disease 
localization between men and women. More cervical 
lymph node TB, which was not correlated with age, 
was diagnosed for female patients. Female sex has in 
general been considered a risk factor for M. tuberculosis 
extrapulmonary TB (24–26). However, this ﬁ  nding has not 
been described for M. bovis TB. Various explanations have 
been given for this gender difference in TB. One possible 
explanation could be a difference in the immunity to M. 
tuberculosis complex infection. Several studies have been 
conducted in humans to compare the immune response in 
both sexes. Differences in reaction among others in TNF 
and interleukin-10 production have been found (27,28). 
Another explanation for this ﬁ  nding may be related to the 
route of infection. Men could be more likely to become 
infected through the tracheal route by aerosols from diseased 
cattle, whereas women become infected by ingesting M. 
bovis while preparing or consuming contaminated food. 
Lastly, smoking has also been identiﬁ  ed as a risk factor for 
pulmonary TB (25), which (assuming a higher percentage 
of men are smokers) could explain the difference we found 
in our study that men have more pulmonary M. bovis 
disease than women. Unfortunately, we could not retrieve 
smoking status from the databases.
The geographic distribution of M. bovis TB in the 
Netherlands showed a proportional increase in M. bovis 
infections in the major cities in the western part of the 
Netherlands during 1993–2007. This ﬁ  nding  probably 
reﬂ  ects the population demographics of the Netherlands, 
where most persons live in and between major cities, but 
also by the facts that immigrants mainly live in major cities 
and that the elderly persons who contracted M. bovis TB in 
the prepasteurization era are undergoing a natural decline 
in health.
We showed that, in 37 (17.1%) of the 217 patients, 
treatment of M. bovis disease cases in this study was not 
compliant with international guidelines. Although all M. 
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Table 1. Clinical and demographic data for Mycobacterium bovis
TB case-patients, by sex, as recorded in the Netherlands 
Tuberculosis Registry, the Netherlands, 1993–2007* 
Characteristic
Dutch,
no. (%),  
n = 138 
Foreign-born, 
no. (%),† 
n = 93 
Total,
no. (%), 
N = 231 
All case-patients 
  M  56 (40.6)  49 (52.7)  105 (45.5) 
  F  82 (59.4)  44 (47.3)  126 (54.5) 
Age, y 
 0–60  115  (49.7) 
  M  13 45
  F  22 35
 >60  116  (50.3) 
  M   4 3 4
  F   6 0 9
Localization 
 Pulmonary  80  (34.6) 
  M  26 25
  F  22‡ 7§
  Respiratory tract  19 (8.2) 
  M   5 5
  F   8 1
  Meningeal and CNS  6 (2.5) 
   M  2 0
  F   F 0
  Intestinal tract  13 (5.6) 
  M   0 3
  F   5 5
  Bone and joint   12 (5.2) 
  M   4 2
  F   5 1
  Urogenital tract  13 (5.6) 
  M   4 3
  F   4 2
  Other organs (e.g., lymph nodes) 59 (25.5) 
  M   5 9
  F  24¶ 21#
 Miliary  TB  11  (4.8) 
  M   6 0
  F   3 2
 Unknown  18  (7.8) 
  M   4 2
  F   7 5
*TB, tuberculosis; CNS, central nervous system. 
†Foreign-born patients originated from other European countries (n = 6), 
Africa (n = 69), Asia (n = 9), South America (n = 3), and unknown areas (n 
= 6). 
‡p = 0.018. 
§p<0.001. 
¶p = 0.004. 
#p = 0.002. RESEARCH
tuberculosis complex isolates in the Netherlands undergo 
drug susceptibility testing, apparently the results of such 
testing do not reach clinicians. Recognition of M. bovis 
as the causative agent of TB does not in itself lead to the 
conclusion that adjustment of the therapy is required; many 
physicians only make adjustments after receiving the results 
of drug susceptibility testing, which usually arrive quite late 
because of the slow growth of M. bovis. Moreover, the quick 
molecular identiﬁ  cation of cultured M. bovis still implies a 
culture delay of ≈4 weeks. Better education of physicians 
and increasing future application of direct molecular 
identiﬁ  cation of M. bovis from clinical samples, i.e., sputum 
or lymph node aspirates, is therefore needed.
The overall proportion of deaths among patients with M. 
bovis disease was higher (19.9%) than that among patients 
with M. tuberculosis disease (4.4%) in the Netherlands. 
The mortality rates during 1993–2007 were 5.2% for M. 
bovis disease versus 1.9% for M. tuberculosis disease. 
This result is probably related to the higher prevalence of 
miliary and central nervous system localization of M. bovis 
disease. Death rates from other, non–TB-related, causes for 
patients with M. bovis infection were 14.7% compared with 
2.5% for M. tuberculosis infection (8). Subgroup analysis 
of M. bovis showed that the proportion of deaths was higher 
among Dutch than among foreign-born patients, but this 
result most likely correlates with age and impairment of 
immunity (10,11,29).
We cannot explain the unexpected trend in lower 
survival of female patients after an episode of M. bovis 
disease. Previous studies have shown that male sex is a risk 
factor for unsuccessful treatment (30,31), but the numbers 
in our study were too small to draw any ﬁ  rm conclusions.
This study had limitations. First, the analysis of the 
results was hampered by the relatively low number of 
foreign-born patients (n = 93) and the heterogeneous nature 
of the study population. Therefore, only data concerning 
patients from Morocco (n = 54) could be analyzed 
separately, and differences with the Dutch case-patients 
were found in terms of age, mortality rate, and primary 
localization of disease.
Another limitation is that a distinction could not 
be made between native Dutch and second-generation 
immigrants born in the Netherlands. This lack of distinction 
implies that some patients have roots in a foreign country 
where the risk for M. bovis TB could be higher.
In conclusion, the incidence of M. bovis disease in 
the Netherlands is comparable to that in other countries in 
which control programs for M. bovis infection are enforced. 
Gender differences in clinical features and mortality rates 
were found in our cohort of patients. The disease now 
mainly infects immigrants from Morocco and elderly 
Dutch citizens. Anti-TNF-α treatment is an emerging cause 
of endogenous reactivation of M. bovis disease in elderly 
Dutch patients, as occurred in 2 of the recent bovine TB 
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Table 2. Treatment results according to age, sex, and localization of Mycobacterium bovis disease in Dutch and foreign-born case-
patients, as recorded in the National Tuberculosis Registry, the Netherlands, 1993–2007* 
Variable
No. (%) Dutch patients, n = 138 No. (%) foreign-born patients, n = 93
Treatment 
completed
Cause of death 
Other† 
Treatment 
completed
Cause of death 
Other†  TB-related Non–TB-related TB-related Non–TB-related
Total 85 (61.6)  10 (7.2)  28 (20.3)  15 (10.9) 66 (71.0)  2 (2.1)  6 (6.5)  19 (20.4)
Age, y
0–60 25 1 3 6 59 2 3 16
 >60  60 9 25 9 7 0 3 3
Sex
 M  33 3 18 2 35 0 3 11
 F  52 7 10 13 31 2 3 8
Localization 
Pulmonary 26 2 9 3 21 0 2 5
 Extrapulmonary  52 5 11 10 44 0 3 11
 Pulmonary  and   
 extrapulmonary 
73 8 21 2 1 3
*TB, tuberculosis. 
†Treatment not completed or treatment continued elsewhere. 
Table 3. Correlation of overall deaths from Mycobacterium bovis
disease with demographic variables, the Netherlands, 1993–
2007*
Variable p value
Sex 0.31
Age >60 y  <0.0001 
Dutch nationality  0.001 
Disease localization (miliary TB)  <0.0001 
*F
2test. TB, tuberculosis. 
Table 4. Correlation of TB-related and non–TB-related deaths 
according to demographic variables, the Netherlands, 1993–
2007*
Variable p value
Sex 0.58
Age >60 y  0.03
Dutch nationality  0.91
Disease localization (miliary TB)  0.49
*F
2test. TB, tuberculosis. M. bovis Disease, the Netherlands
cases described in this article; reactivation may be slower 
than for M. tuberculosis infection.
Dr Majoor is a pulmonologist in the Academic Medical 
Center in Amsterdam. His main research interests are asthma, 
cystic ﬁ  brosis, and TB.
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